Table 1.
MS patients
| Age (years) | Enhanced TLR2 response | Tested/response | Whole CD14+ | ||||
|---|---|---|---|---|---|---|---|
| MS | Treatment | M/F | PBMC | Single‐cell | |||
| Pr Prog | None | F | 60 | Yes | E | ||
| Pr Prog | None | F | 68 | N | |||
| Pr Prog | Avonex | F | 65 | Yes | E | ||
| Pr Prog | None | F | 29 | N | N | ||
| Pr Prog | None | F | 60 | N | |||
| Prog Rel | None | F | 51 | Yes | E | E | |
| Sec Prog | Rituximab | M | 36 | Yes | E | E | |
| Sec Prog | Tysabri | F | 61 | Yes | E | N | |
| Sec Prog | None | M | 70 | Yes | E | ||
| Sec Prog | Tysabri | F | 47 | Yes | E | ||
| RRMS | None | F | 39 | N | |||
| RRMS | Tysabri | F | 41 | N | |||
| RRMS | Copaxone | M | 53 | Yes | E | E | E |
| RRMS | Copaxone | F | 59 | Yes | E | ||
| RRMS | Tysabri | F | 58 | N | |||
| RRMS | none | F | 49 | N | |||
| RRMS | Rituximab | F | 55 | N | |||
| RRMS | Rituximab | F | 21 | Yes | E | ||
| RRMS | Avonex | F | 58 | N | |||
| RRMS | Tecfidera | M | 51 | N | |||
| RRMS | None | F | 62 | N | |||
| RRMS | Tysabri | F | 29 | Yes | E | ||
| RRMS | Gilenya | F | 50 | N | |||
| RRMS | Tysabri | F | 49 | N | |||
| RRMS | Gilenya | F | 31 | Yes | E | ||
| RRMS | None | F | 31 | Yes | E |
E = enhanced response; N = normal response; Pr Prog = primary progressive MS; Prog Rel = progressive relapsing MS; RRMS = relapsing–remitting MS; Sec Prog = secondary progressive MS; TLR = Toll‐like receptor; PBMC = peripheral blood mononuclear cells; M/F = male/female.